Aripiprazole and dehydroaripiprazole
- Description
- Aripiprazole and dehydroaripiprazole measured by LC-MS/MS
- Clinical details
Aripiprazole is an atypical antipsychotic with a novel structure. It is used at a dose of 10-15 mg once daily, up to a maximum of 30 mg/d. Aripiprazole undergoes extensive hepatic metabolism via CYP2D6 and CYP3A4 including dehydrogenation, hydroxylation, and N-dealkylation. Dehydroaripiprazole has pharmacological activity, and accumulates in plasma to ca. 40 % of the aripiprazole concentration at steady-state, which is achieved in about 14 days. The plasma half-life averages 75 h (aripiprazole) and 94 h (dehydroaripiprazole). Aripiprazole and dehydroaripiprazole assay is useful in assessing adherence and may help in dose optimisation, and if acute poisoning is suspected. A reference range of 150-300 µg/L of aripiprazole (60-120 µg/L dehydroaripiprazole) has been suggested (12 h post-dose sample).
- Reference range
150-300
- Units
µg/L
- Synonyms
Abilify
- Testing site
- Synnovis : Reference Services : Blackfriars Hub
- Laboratory
- Therapeutic Drug Monitoring
- Sample type and volume required
4 mL of ETDA whole blood is preferred (pre-dose or ‘rough’ sample). Serum or plasma can be used if required, but please avoid gel-separator tubes.
- Storage and transport
Please refrigerate (if possible) if not sending immediately. Send by first class post.
- Turnaround time
5 working days